MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.
18 years or older at the time of consent
A known diagnosis of interstitial lung disease
Diffusing capacity for carbon monoxide (DLCO) <30% predicted, collected within 3 months prior to consent
Willing and able to provide informed consent and undergo all study-specific procedures, including echo and RHC, if required
A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))
A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent
LV ejection fraction ≤ 40% on most recent echo or cardiac MRI, if available
Unclassifiable Tempus PH ECG risk result after up to 2 ECG acquisitions
Tempus AI
Lead sponsor
United Therapeutics
Collaborator